5-Iodotubercidin

Biological Activity

5-Iodotubercidin is a potent adenosine kinase inhibitor (IC₅₀ = 26 nM). Also nucleoside transporter inhibitor (IC₅₀ values are < 25 nM, 7 μM and 15 μM for inhibition of [³H]adenosine, [³H]uridine and [³H]formycin B uptake respectively). Strongly stimulates glycogen synthesis in hepatocytes via activation of glycogen synthase. Also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2 and PKC (IC₅₀ values are 0.4, 3.5, 5-10, 5-10, 10.9 and 27.7 μM respectively). Decreases hippocampal DNA methylation through adenosine kinase inhibition in vivo.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.
   Pisanti S, Picardi P, Ciaglia E, Margarucci L, Ronca R, Giacomini A, Malfitano A, Casapullo A, Laezza C, Gazzerro P, Bifulco M
   FASEB J, 2014;28(3):1132-44.
2. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.
   Williams-Karnesky et al.
   J.Clin.Invest., 2013;123:3552
3. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor.
   Massillon et al.
   Biochem.J., 1994;299:123
4. Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT₁ MF-2 smooth muscle cells.
   Parkinson and Geiger
   J.Pharmacol.Exp.Ther., 1996;277:1397
5. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.
   Ugarkar et al.
   J.Med.Chem., 2000;43:2883

Product Datasheets